Zoetis Inc Asset Resilience Ratio
Zoetis Inc asset resilience ratio. Zoetis Inc (ZTS) has an Asset Resilience Ratio of 12.20% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Zoetis Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zoetis Inc (2013–2024)
Asset resilience ratio of Zoetis Inc from 2013 to 2024. This chart shows how Zoetis Inc's Asset Resilience Ratio has changed over time. See ZTS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Zoetis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZTS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.72 Billion | 12.2% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.72 Billion | 12.20% |
Asset Resilience Insights
- Moderate Liquidity: Zoetis Inc has 12.20% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Zoetis Inc Industry Peers by Asset Resilience Ratio
Compare Zoetis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Zoetis Inc Asset Resilience Ratio by Year (2013–2024)
Zoetis Inc asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Zoetis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.96% | $1.99 Billion | $14.24 Billion | -0.32pp |
| 2023-12-31 | 14.27% | $2.04 Billion | $14.29 Billion | -9.69pp |
| 2022-12-31 | 23.97% | $3.58 Billion | $14.93 Billion | -1.08pp |
| 2021-12-31 | 25.05% | $3.48 Billion | $13.90 Billion | -1.43pp |
| 2020-12-31 | 26.48% | $3.60 Billion | $13.61 Billion | +9.71pp |
| 2019-12-31 | 16.77% | $1.94 Billion | $11.54 Billion | +0.99pp |
| 2018-12-31 | 15.78% | $1.70 Billion | $10.78 Billion | -2.43pp |
| 2017-12-31 | 18.22% | $1.56 Billion | $8.59 Billion | +8.71pp |
| 2016-12-31 | 9.50% | $727.00 Million | $7.65 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $7.91 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.59 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $6.56 Billion | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more